>P00125_A01 abituzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGACATCAGCAACTACCTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACTACACCAGCAAGATCCACAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTACACCTTCACCATCAGCAGCCTGCAGCCC
GAGGACATCGCCACCTACTACTGCCAGCAGGGCAACACCTTCCCCTACACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00125_A02 abrilumab
GACATCCAGATGACCCAGAGCCCCAGCAGCGTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGGCATCAGCAGCTGGCTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACGGCGCCAGCAACCTGGAGAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCAACTACTACTGCCAGCAGGCCAACAGCTTCCCCTGGACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00125_A03 adalimumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGGCATCAGGAACTACCTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACGCCGCCAGCACCCTGCAGAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACGTGGCCACCTACTACTGCCAGAGGTACAACAGGGCCCCCTACACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>>P00125_A04 alemtuzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAAGGCCAGCCAGAACATCGACAAGTACCTGAACTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACAACACCAACAACCTGCAGACCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCTTCACCATCAGCAGCCTGCAGCCC
GAGGACATCGCCACCTACTACTGCCTGCAGCACATCAGCAGGCCCAGGACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00125_A05 alirocumab
GACATCGTGATGACCCAGAGCCCCGACAGCCTGGCCGTGAGCCTGGGCGAGAGGGCCACC
ATCAACTGCAAGAGCAGCCAGAGCGTGCTGTACAGGAGCAACAACAGGAACTTCCTGGGC
TGGTACCAGCAGAAGCCCGGCCAGCCCCCCAACCTGCTGATCTACTGGGCCAGCACCAGG
GAGAGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACC
ATCAGCAGCCTGCAGGCCGAGGACGTGGCCGTGTACTACTGCCAGCAGTACTACACCACC
CCCTACACCTTCGGCCAGGGCACCAAGCTGGAGATCAAG
>P00125_A06 anifrolumab
GAGATCGTGCTGACCCAGAGCCCCGGCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCAGCTTCTTCGCCTGGTACCAGCAGAAG
CCCGGCCAGGCCCCCAGGCTGCTGATCTACGGCGCCAGCAGCAGGGCCACCGGCATCCCC
GACAGGCTGAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCACCAGGCTGGAG
CCCGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGACAGCAGCGCCATCACCTTCGGC
CAGGGCACCAGGCTGGAGATCAAG
>P00125_A07 atezolizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGACGTGAGCACCGCCGTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACAGCGCCAGCTTCCTGTACAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGTACCTGTACCACCCCGCCACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00125_A08 bapineuzumab
GACGTGGTGATGACCCAGAGCCCCCTGAGCCTGCCCGTGACCCCCGGCGAGCCCGCCAGC
ATCAGCTGCAAGAGCAGCCAGAGCCTGCTGGACAGCGACGGCAAGACCTACCTGAACTGG
CTGCTGCAGAAGCCCGGCCAGAGCCCCCAGAGGCTGATCTACCTGGTGAGCAAGCTGGAC
AGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAAGATC
AGCAGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCTGGCAGGGCACCCACTTCCCC
AGGACCTTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P00125_A09 basiliximab
CAGATCGTGAGCACCCAGAGCCCCGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACC
ATGACCTGCAGCGCCAGCAGCAGCAGGAGCTACATGCAGTGGTACCAGCAGAAGCCCGGC
ACCAGCCCCAAGAGGTGGATCTACGACACCAGCAAGCTGGCCAGCGGCGTGCCCGCCAGG
TTCAGCGGCAGCGGCAGCGGCACCAGCTACAGCCTGACCATCAGCAGCATGGAGGCCGAG
GACGCCGCCACCTACTACTGCCACCAGAGGAGCAGCTACACCTTCGGCGGCGGCACCAAG
CTGGAGATCAAG
>P00125_A10 bavituximab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCCTGGGCGAGAGGGTGAGC
CTGACCTGCAGGGCCAGCCAGGACATCGGCAGCAGCCTGAACTGGCTGCAGCAGGGCCCC
GACGGCACCATCAAGAGGCTGATCTACGCCACCAGCAGCCTGGACAGCGGCGTGCCCAAG
AGGTTCAGCGGCAGCAGGAGCGGCAGCGACTACAGCCTGACCATCAGCAGCCTGGAGAGC
GAGGACTTCGTGGACTACTACTGCCTGCAGTACGTGAGCAGCCCCCCCACCTTCGGCGCC
GGCACCAAGCTGGAGCTGAAG
>P00125_A11 belimumab
AGCAGCGAGCTGACCCAGGACCCCGCCGTGAGCGTGGCCCTGGGCCAGACCGTGAGGGTG
ACCTGCCAGGGCGACAGCCTGAGGAGCTACTACGCCAGCTGGTACCAGCAGAAGCCCGGC
CAGGCCCCCGTGCTGGTGATCTACGGCAAGAACAACAGGCCCAGCGGCATCCCCGACAGG
TTCAGCGGCAGCAGCAGCGGCAACACCGCCAGCCTGACCATCACCGGCGCCCAGGCCGAG
GACGAGGCCGACTACTACTGCAGCAGCAGGGACAGCAGCGGCAACCACTGGGTGTTCGGC
GGCGGCACCGAGCTGACCGTGCTG
>P00125_A12 benralizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCGGCACCAGCGAGGACATCATCAACTACCTGAACTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACCACACCAGCAGGCTGCAGAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGGGCTACACCCTGCCCTACACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00125_B01 bevacizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGCGCCAGCCAGGACATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGGTGCTGATCTACTTCACCAGCAGCCTGCACAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGTACAGCACCGTGCCCTGGACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00125_B02 bimagrumab
CAGAGCGCCCTGACCCAGCCCGCCAGCGTGAGCGGCAGCCCCGGCCAGAGCATCACCATC
AGCTGCACCGGCACCAGCAGCGACGTGGGCAGCTACAACTACGTGAACTGGTACCAGCAG
CACCCCGGCAAGGCCCCCAAGCTGATGATCTACGGCGTGAGCAAGAGGCCCAGCGGCGTG
AGCAACAGGTTCAGCGGCAGCAAGAGCGGCAACACCGCCAGCCTGACCATCAGCGGCCTG
CAGGCCGAGGACGAGGCCGACTACTACTGCGGCACCTTCGCCGGCGGCAGCTACTACGGC
GTGTTCGGCGGCGGCACCAAGCTGACCGTGCTG
>P00863_B03 blosozumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAAGGCCAGCCAGGACGTGCACACCGCCGTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACTGGGCCAGCACCAGGTGGACCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGTACAGCGACTACCCCTGGACCTTCGGCGGC
GGCACCAAGGTGGAGATCAAG
>P00863_B04 bococizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGGCATCAGCAGCGCCCTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACAGCGCCAGCTACAGGTACACCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCTTCACCATCAGCAGCCTGCAGCCC
GAGGACATCGCCACCTACTACTGCCAGCAGAGGTACAGCCTGTGGAGGACCTTCGGCCAG
GGCACCAAGCTGGAGATCAAG
>P00863_B05 brentuximab
GACATCGTGCTGACCCAGAGCCCCGCCAGCCTGGCCGTGAGCCTGGGCCAGAGGGCCACC
ATCAGCTGCAAGGCCAGCCAGAGCGTGGACTTCGACGGCGACAGCTACATGAACTGGTAC
CAGCAGAAGCCCGGCCAGCCCCCCAAGGTGCTGATCTACGCCGCCAGCAACCTGGAGAGC
GGCATCCCCGCCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAACATCCAC
CCCGTGGAGGAGGAGGACGCCGCCACCTACTACTGCCAGCAGAGCAACGAGGACCCCTGG
ACCTTCGGCGGCGGCACCAAGCTGGAGATCAAG
>P00863_B06 briakinumab
CAGAGCGTGCTGACCCAGCCCCCCAGCGTGAGCGGCGCCCCCGGCCAGAGGGTGACCATC
AGCTGCAGCGGCAGCAGGAGCAACATCGGCAGCAACACCGTGAAGTGGTACCAGCAGCTG
CCCGGCACCGCCCCCAAGCTGCTGATCTACTACAACGACCAGAGGCCCAGCGGCGTGCCC
GACAGGTTCAGCGGCAGCAAGAGCGGCACCAGCGCCAGCCTGGCCATCACCGGCCTGCAG
GCCGAGGACGAGGCCGACTACTACTGCCAGAGCTACGACAGGTACACCCACCCCGCCCTG
CTGTTCGGCACCGGCACCAAGGTGACCGTGCTG
>P00863_B07 brodalumab
GAGATCGTGATGACCCAGAGCCCCGCCACCCTGAGCGTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCAACCTGGCCTGGTTCCAGCAGAAGCCC
GGCCAGGCCCCCAGGCCCCTGATCTACGACGCCAGCACCAGGGCCACCGGCGTGCCCGCC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGAGC
GAGGACTTCGCCGTGTACTACTGCCAGCAGTACGACAACTGGCCCCTGACCTTCGGCGGC
GGCACCAAGGTGGAGATCAAG
>P00863_B08 canakinumab
GAGATCGTGCTGACCCAGAGCCCCGACTTCCAGAGCGTGACCCCCAAGGAGAAGGTGACC
ATCACCTGCAGGGCCAGCCAGAGCATCGGCAGCAGCCTGCACTGGTACCAGCAGAAGCCC
GACCAGAGCCCCAAGCTGCTGATCAAGTACGCCAGCCAGAGCTTCAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAACAGCCTGGAGGCC
GAGGACGCCGCCGCCTACTACTGCCACCAGAGCAGCAGCCTGCCCTTCACCTTCGGCCCC
GGCACCAAGGTGGACATCAAG
>P00863_B09 carlumab
GAGATCGTGCTGACCCAGAGCCCCGCCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCGACGCCTACCTGGCCTGGTACCAGCAGAAG
CCCGGCCAGGCCCCCAGGCTGCTGATCTACGACGCCAGCAGCAGGGCCACCGGCGTGCCC
GCCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGGAG
CCCGAGGACTTCGCCGTGTACTACTGCCACCAGTACATCCAGCTGCACAGCTTCACCTTC
GGCCAGGGCACCAAGGTGGAGATCAAG
>P00863_B10 certolizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAAGGCCAGCCAGAACGTGGGCACCAACGTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGGCCCTGATCTACAGCGCCAGCTTCCTGTACAGCGGCGTGCCCTAC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGTACAACATCTACCCCCTGACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00863_B11 cetuximab
GACATCCTGCTGACCCAGAGCCCCGTGATCCTGAGCGTGAGCCCCGGCGAGAGGGTGAGC
TTCAGCTGCAGGGCCAGCCAGAGCATCGGCACCAACATCCACTGGTACCAGCAGAGGACC
AACGGCAGCCCCAGGCTGCTGATCAAGTACGCCAGCGAGAGCATCAGCGGCATCCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAGCATCAACAGCGTGGAGAGC
GAGGACATCGCCGACTACTACTGCCAGCAGAACAACAACTGGCCCACCACCTTCGGCGCC
GGCACCAAGCTGGAGCTGAAG
>P00863_B12 cixutumumab
AGCAGCGAGCTGACCCAGGACCCCGCCGTGAGCGTGGCCCTGGGCCAGACCGTGAGGATC
ACCTGCCAGGGCGACAGCCTGAGGAGCTACTACGCCACCTGGTACCAGCAGAAGCCCGGC
CAGGCCCCCATCCTGGTGATCTACGGCGAGAACAAGAGGCCCAGCGGCATCCCCGACAGG
TTCAGCGGCAGCAGCAGCGGCAACACCGCCAGCCTGACCATCACCGGCGCCCAGGCCGAG
GACGAGGCCGACTACTACTGCAAGAGCAGGGACGGCAGCGGCCAGCACCTGGTGTTCGGC
GGCGGCACCAAGCTGACCGTGCTG
>P00863_C01 clazakizumab
GCCATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCCAGGCCAGCCAGAGCATCAACAACGAGCTGAGCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACAGGGCCAGCACCCTGGCCAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GACGACTTCGCCACCTACTACTGCCAGCAGGGCTACAGCCTGAGGAACATCGACAACGCC
TTCGGCGGCGGCACCAAGGTGGAGATCAAG
>P00863_C02 codrituzumab
GACGTGGTGATGACCCAGAGCCCCCTGAGCCTGCCCGTGACCCCCGGCGAGCCCGCCAGC
ATCAGCTGCAGGAGCAGCCAGAGCCTGGTGCACAGCAACAGGAACACCTACCTGCACTGG
TACCTGCAGAAGCCCGGCCAGAGCCCCCAGCTGCTGATCTACAAGGTGAGCAACAGGTTC
AGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAAGATC
AGCAGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCAGCCAGAACACCCACGTGCCC
CCCACCTTCGGCCAGGGCACCAAGCTGGAGATCAAG
>P00863_C03 crenezumab
GACATCGTGATGACCCAGAGCCCCCTGAGCCTGCCCGTGACCCCCGGCGAGCCCGCCAGC
ATCAGCTGCAGGAGCAGCCAGAGCCTGGTGTACAGCAACGGCGACACCTACCTGCACTGG
TACCTGCAGAAGCCCGGCCAGAGCCCCCAGCTGCTGATCTACAAGGTGAGCAACAGGTTC
AGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAAGATC
AGCAGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCAGCCAGAGCACCCACGTGCCC
TGGACCTTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P00863_C04 dacetuzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGAGCAGCCAGAGCCTGGTGCACAGCAACGGCAACACCTTCCTGCACTGG
TACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACACCGTGAGCAACAGGTTC
AGCGGCGTGCCCAGCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATC
AGCAGCCTGCAGCCCGAGGACTTCGCCACCTACTTCTGCAGCCAGACCACCCACGTGCCC
TGGACCTTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P00863_C05 daclizumab
GACATCCAGATGACCCAGAGCCCCAGCACCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGCGCCAGCAGCAGCATCAGCTACATGCACTGGTACCAGCAGAAGCCCGGC
AAGGCCCCCAAGCTGCTGATCTACACCACCAGCAACCTGGCCAGCGGCGTGCCCGCCAGG
TTCAGCGGCAGCGGCAGCGGCACCGAGTTCACCCTGACCATCAGCAGCCTGCAGCCCGAC
GACTTCGCCACCTACTACTGCCACCAGAGGAGCACCTACCCCCTGACCTTCGGCCAGGGC
ACCAAGGTGGAGGTGAAG
>P00863_C06 dalotuzumab
GACATCGTGATGACCCAGAGCCCCCTGAGCCTGCCCGTGACCCCCGGCGAGCCCGCCAGC
ATCAGCTGCAGGAGCAGCCAGAGCATCGTGCACAGCAACGGCAACACCTACCTGCAGTGG
TACCTGCAGAAGCCCGGCCAGAGCCCCCAGCTGCTGATCTACAAGGTGAGCAACAGGCTG
TACGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAAGATC
AGCAGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCTTCCAGGGCAGCCACGTGCCC
TGGACCTTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P00863_C07 daratumumab
GAGATCGTGCTGACCCAGAGCCCCGCCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCTACCTGGCCTGGTACCAGCAGAAGCCC
GGCCAGGCCCCCAGGCTGCTGATCTACGACGCCAGCAACAGGGCCACCGGCATCCCCGCC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGGAGCCC
GAGGACTTCGCCGTGTACTACTGCCAGCAGAGGAGCAACTGGCCCCCCACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00863_C08 denosumab
GAGATCGTGCTGACCCAGAGCCCCGGCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGGGGCAGGTACCTGGCCTGGTACCAGCAGAAG
CCCGGCCAGGCCCCCAGGCTGCTGATCTACGGCGCCAGCAGCAGGGCCACCGGCATCCCC
GACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGGCTGGAG
CCCGAGGACTTCGCCGTGTTCTACTGCCAGCAGTACGGCAGCAGCCCCAGGACCTTCGGC
CAGGGCACCAAGGTGGAGATCAAG
>P00863_C09 dinutuximab
GAGATCGTGATGACCCAGAGCCCCGCCACCCTGAGCGTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGAGCAGCCAGAGCCTGGTGCACAGGAACGGCAACACCTACCTGCACTGG
TACCTGCAGAAGCCCGGCCAGAGCCCCAAGCTGCTGATCCACAAGGTGAGCAACAGGTTC
AGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAAGATC
AGCAGGGTGGAGGCCGAGGACCTGGGCGTGTACTTCTGCAGCCAGAGCACCCACGTGCCC
CCCCTGACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAG
>P00863_C10 drozitumab
AGCGAGCTGACCCAGGACCCCGCCGTGAGCGTGGCCCTGGGCCAGACCGTGAGGATCACC
TGCAGCGGCGACAGCCTGAGGAGCTACTACGCCAGCTGGTACCAGCAGAAGCCCGGCCAG
GCCCCCGTGCTGGTGATCTACGGCGCCAACAACAGGCCCAGCGGCATCCCCGACAGGTTC
AGCGGCAGCAGCAGCGGCAACACCGCCAGCCTGACCATCACCGGCGCCCAGGCCGAGGAC
GAGGCCGACTACTACTGCAACAGCGCCGACAGCAGCGGCAACCACGTGGTGTTCGGCGGC
GGCACCAAGCTGACCGTGCTG
>P00863_C11 duligotuzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGAACATCGCCACCGACGTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACAGCGCCAGCTTCCTGTACAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGAGCGAGCCCGAGCCCTACACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00863_C12 dupilumab
GACATCGTGATGACCCAGAGCCCCCTGAGCCTGCCCGTGACCCCCGGCGAGCCCGCCAGC
ATCAGCTGCAGGAGCAGCCAGAGCCTGCTGTACAGCATCGGCTACAACTACCTGGACTGG
TACCTGCAGAAGAGCGGCCAGAGCCCCCAGCTGCTGATCTACCTGGGCAGCAACAGGGCC
AGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAAGATC
AGCAGGGTGGAGGCCGAGGACGTGGGCTTCTACTACTGCATGCAGGCCCTGCAGACCCCC
TACACCTTCGGCCAGGGCACCAAGCTGGAGATCAAG
>P00863_D01 eculizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCGGCGCCAGCGAGAACATCTACGGCGCCCTGAACTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACGGCGCCACCAACCTGGCCGACGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGAACGTGCTGAACACCCCCCTGACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00863_D02 efalizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCAAGACCATCAGCAAGTACCTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACAGCGGCAGCACCCTGCAGAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGCACAACGAGTACCCCCTGACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P01274_D03 eldelumab
GAGATCGTGCTGACCCAGAGCCCCGGCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCAGCTACCTGGCCTGGTACCAGCAGAAG
CCCGGCCAGGCCCCCAGGCTGCTGATCTACGGCGCCAGCAGCAGGGCCACCGGCATCCCC
GACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGGCTGGAG
CCCGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGGCAGCAGCCCCATCTTCACCTTC
GGCCCCGGCACCAAGGTGGACATCAAG
>P01274_D04 elotuzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAAGGCCAGCCAGGACGTGGGCATCGCCGTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGTGCCCAAGCTGCTGATCTACTGGGCCAGCACCAGGCACACCGGCGTGCCCGAC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACGTGGCCACCTACTACTGCCAGCAGTACAGCAGCTACCCCTACACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P01274_D05 emibetuzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGCGTGAGCAGCAGCGTGAGCAGCATCTACCTGCACTGGTACCAGCAGAAG
CCCGGCAAGGCCCCCAAGCTGCTGATCTACAGCACCAGCAACCTGGCCAGCGGCGTGCCC
AGCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAG
CCCGAGGACTTCGCCACCTACTACTGCCAGGTGTACAGCGGCTACCCCCTGACCTTCGGC
GGCGGCACCAAGGTGGAGATCAAG
>P01274_D06 enokizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAAGGCCAGCCAGCACGTGATCACCCACGTGACCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACGGCACCAGCTACAGCTACAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGTTCTACGAGTACCCCCTGACCTTCGGCGGC
GGCACCAAGGTGGAGATCAAG
>P01274_D07 epratuzumab
GACATCCAGCTGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATGAGCTGCAAGAGCAGCCAGAGCGTGCTGTACAGCGCCAACCACAAGAACTACCTGGCC
TGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACTGGGCCAGCACCAGG
GAGAGCGGCGTGCCCAGCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCTTCACC
ATCAGCAGCCTGCAGCCCGAGGACATCGCCACCTACTACTGCCACCAGTACCTGAGCAGC
TGGACCTTCGGCGGCGGCACCAAGCTGGAGATCAAG
>P01274_D08 etrolizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCGAGAGCGTGGACGACCTGCTGCACTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCAAGTACGCCAGCCAGAGCATCAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGGGCAACAGCCTGCCCAACACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P01274_D09 evolocumab
GAGAGCGCCCTGACCCAGCCCGCCAGCGTGAGCGGCAGCCCCGGCCAGAGCATCACCATC
AGCTGCACCGGCACCAGCAGCGACGTGGGCGGCTACAACAGCGTGAGCTGGTACCAGCAG
CACCCCGGCAAGGCCCCCAAGCTGATGATCTACGAGGTGAGCAACAGGCCCAGCGGCGTG
AGCAACAGGTTCAGCGGCAGCAAGAGCGGCAACACCGCCAGCCTGACCATCAGCGGCCTG
CAGGCCGAGGACGAGGCCGACTACTACTGCAACAGCTACACCAGCACCAGCATGGTGTTC
GGCGGCGGCACCAAGCTGACCGTGCTG
>P01274_D10 farletuzumab
GACATCCAGCTGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGCGTGAGCAGCAGCATCAGCAGCAACAACCTGCACTGGTACCAGCAGAAG
CCCGGCAAGGCCCCCAAGCCCTGGATCTACGGCACCAGCAACCTGGCCAGCGGCGTGCCC
AGCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTACACCTTCACCATCAGCAGCCTGCAG
CCCGAGGACATCGCCACCTACTACTGCCAGCAGTGGAGCAGCTACCCCTACATGTACACC
TTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P01274_D11 fasinumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGCCGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGCCATCAGGAACGACCTGGGCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGAGGCTGATCTACGCCGCCTTCAACCTGCAGAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGAGTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACCTGGCCAGCTACTACTGCCAGCAGTACAACAGGTACCCCTGGACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P01274_D12 fezakinumab
CAGGCCGTGCTGACCCAGCCCCCCAGCGTGAGCGGCGCCCCCGGCCAGAGGGTGACCATC
AGCTGCACCGGCAGCAGCAGCAACATCGGCGCCGGCTACGGCGTGCACTGGTACCAGCAG
CTGCCCGGCACCGCCCCCAAGCTGCTGATCTACGGCGACAGCAACAGGCCCAGCGGCGTG
CCCGACAGGTTCAGCGGCAGCAAGAGCGGCACCAGCGCCAGCCTGGCCATCACCGGCCTG
CAGGCCGAGGACGAGGCCGACTACTACTGCCAGAGCTACGACAACAGCCTGAGCGGCTAC
GTGTTCGGCGGCGGCACCCAGCTGACCGTGCTG
>P01274_E01 ficlatuzumab
GACATCGTGATGACCCAGAGCCCCGACAGCCTGGCCATGAGCCTGGGCGAGAGGGTGACC
CTGAACTGCAAGGCCAGCGAGAACGTGGTGAGCTACGTGAGCTGGTACCAGCAGAAGCCC
GGCCAGAGCCCCAAGCTGCTGATCTACGGCGCCAGCAACAGGGAGAGCGGCGTGCCCGAC
AGGTTCAGCGGCAGCGGCAGCGCCACCGACTTCACCCTGACCATCAGCAGCGTGCAGGCC
GAGGACGTGGCCGACTACCACTGCGGCCAGAGCTACAACTACCCCTACACCTTCGGCCAG
GGCACCAAGCTGGAGATCAAG
>P01274_E02 figitumumab
GACATCCAGATGACCCAGTTCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGGCATCAGGAACGACCTGGGCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGAGGCTGATCTACGCCGCCAGCAGGCTGCACAGGGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGAGTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCTGCAGCACAACAGCTACCCCTGCAGCTTCGGCCAG
GGCACCAAGCTGGAGATCAAG
>P01274_E03 fletikumab
GCCATCCAGCTGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGGCATCAGCAGCGCCCTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACGACGCCAGCAGCCTGGAGAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGTTCAACAGCTACCCCCTGACCTTCGGCGGC
GGCACCAAGGTGGAGATCAAG
>P01274_E04 foralumab
GAGATCGTGCTGACCCAGAGCCCCGCCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCTACCTGGCCTGGTACCAGCAGAAGCCC
GGCCAGGCCCCCAGGCTGCTGATCTACGACGCCAGCAACAGGGCCACCGGCATCCCCGCC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGGAGCCC
GAGGACTTCGCCGTGTACTACTGCCAGCAGAGGAGCAACTGGCCCCCCCTGACCTTCGGC
GGCGGCACCAAGGTGGAGATCAAG
>P01274_E05 fresolimumab
GAGACCGTGCTGACCCAGAGCCCCGGCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCCTGGGCAGCAGCTACCTGGCCTGGTACCAGCAGAAG
CCCGGCCAGGCCCCCAGGCTGCTGATCTACGGCGCCAGCAGCAGGGCCCCCGGCATCCCC
GACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGGCTGGAG
CCCGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGCCGACAGCCCCATCACCTTCGGC
CAGGGCACCAGGCTGGAGATCAAG
>P01274_E06 fulranumab
GCCATCCAGCTGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGGCATCAGCAGCGCCCTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACGACGCCAGCAGCCTGGAGAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGTTCAACAGCTACCCCCTGACCTTCGGCGGC
GGCACCAAGGTGGAGATCAAG
>P01274_E07 galiximab
GAGAGCGCCCTGACCCAGCCCCCCAGCGTGAGCGGCGCCCCCGGCCAGAAGGTGACCATC
AGCTGCACCGGCAGCACCAGCAACATCGGCGGCTACGACCTGCACTGGTACCAGCAGCTG
CCCGGCACCGCCCCCAAGCTGCTGATCTACGACATCAACAAGAGGCCCAGCGGCATCAGC
GACAGGTTCAGCGGCAGCAAGAGCGGCACCGCCGCCAGCCTGGCCATCACCGGCCTGCAG
ACCGAGGACGAGGCCGACTACTACTGCCAGAGCTACGACAGCAGCCTGAACGCCCAGGTG
TTCGGCGGCGGCACCAGGCTGACCGTGCTG
>P01274_E08 ganitumab
GACGTGGTGATGACCCAGAGCCCCCTGAGCCTGCCCGTGACCCCCGGCGAGCCCGCCAGC
ATCAGCTGCAGGAGCAGCCAGAGCCTGCTGCACAGCAACGGCTACAACTACCTGGACTGG
TACCTGCAGAAGCCCGGCCAGAGCCCCCAGCTGCTGATCTACCTGGGCAGCAACAGGGCC
AGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAAGATC
AGCAGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCATGCAGGGCACCCACTGGCCC
CTGACCTTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P01274_E09 gantenerumab
GACATCGTGCTGACCCAGAGCCCCGCCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCAGCTACCTGGCCTGGTACCAGCAGAAG
CCCGGCCAGGCCCCCAGGCTGCTGATCTACGGCGCCAGCAGCAGGGCCACCGGCGTGCCC
GCCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGGAG
CCCGAGGACTTCGCCACCTACTACTGCCTGCAGATCTACAACATGCCCATCACCTTCGGC
CAGGGCACCAAGGTGGAGATCAAG
>P01274_E10 gemtuzumab
GACATCCAGCTGACCCAGAGCCCCAGCACCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCGAGAGCCTGGACAACTACGGCATCAGGTTCCTGACCTGGTTC
CAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATGTACGCCGCCAGCAACCAGGGCAGC
GGCGTGCCCAGCAGGTTCAGCGGCAGCGGCAGCGGCACCGAGTTCACCCTGACCATCAGC
AGCCTGCAGCCCGACGACTTCGCCACCTACTACTGCCAGCAGACCAAGGAGGTGCCCTGG
AGCTTCGGCCAGGGCACCAAGGTGGAGGTGAAG
>P01274_E11 gevokizumab
GACATCCAGATGACCCAGAGCACCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGACATCAGCAACTACCTGAGCTGGTACCAGCAGAAGCCC
GGCAAGGCCGTGAAGCTGCTGATCTACTACACCAGCAAGCTGCACAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTACACCCTGACCATCAGCAGCCTGCAGCAG
GAGGACTTCGCCACCTACTTCTGCCTGCAGGGCAAGATGCTGCCCTGGACCTTCGGCCAG
GGCACCAAGCTGGAGATCAAG
>P01274_E12 girentuximab
GACATCGTGATGACCCAGAGCCAGAGGTTCATGAGCACCACCGTGGGCGACAGGGTGAGC
ATCACCTGCAAGGCCAGCCAGAACGTGGTGAGCGCCGTGGCCTGGTACCAGCAGAAGCCC
GGCCAGAGCCCCAAGCTGCTGATCTACAGCGCCAGCAACAGGTACACCGGCGTGCCCGAC
AGGTTCACCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAACATGCAGAGC
GAGGACCTGGCCGACTTCTTCTGCCAGCAGTACAGCAACTACCCCTGGACCTTCGGCGGC
GGCACCAAGCTGGAGATCAAG
>P01274_F01 glembatumumab
GAGATCGTGATGACCCAGAGCCCCGCCACCCTGAGCGTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGGACAACAACCTGGTGTGGTACCAGCAGAAGCCC
GGCCAGGCCCCCAGGCTGCTGATCTACGGCGCCAGCACCAGGGCCACCGGCATCCCCGCC
AGGTTCAGCGGCAGCGGCAGCGGCACCGAGTTCACCCTGACCATCAGCAGCCTGCAGAGC
GAGGACTTCGCCGTGTACTACTGCCAGCAGTACAACAACTGGCCCCCCTGGACCTTCGGC
CAGGGCACCAAGGTGGAGATCAAG
>P01274_F02 golimumab
GAGATCGTGCTGACCCAGAGCCCCGCCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGTACAGCTACCTGGCCTGGTACCAGCAGAAGCCC
GGCCAGGCCCCCAGGCTGCTGATCTACGACGCCAGCAACAGGGCCACCGGCATCCCCGCC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGGAGCCC
GAGGACTTCGCCGTGTACTACTGCCAGCAGAGGAGCAACTGGCCCCCCTTCACCTTCGGC
CCCGGCACCAAGGTGGACATCAAG
>P01274_F03 guselkumab
CAGAGCGTGCTGACCCAGCCCCCCAGCGTGAGCGGCGCCCCCGGCCAGAGGGTGACCATC
AGCTGCACCGGCAGCAGCAGCAACATCGGCAGCGGCTACGACGTGCACTGGTACCAGCAG
CTGCCCGGCACCGCCCCCAAGCTGCTGATCTACGGCAACAGCAAGAGGCCCAGCGGCGTG
CCCGACAGGTTCAGCGGCAGCAAGAGCGGCACCAGCGCCAGCCTGGCCATCACCGGCCTG
CAGAGCGAGGACGAGGCCGACTACTACTGCGCCAGCTGGACCGACGGCCTGAGCCTGGTG
GTGTTCGGCGGCGGCACCAAGCTGACCGTGCTG
>P01274_F04 ibalizumab
GACATCGTGATGACCCAGAGCCCCGACAGCCTGGCCGTGAGCCTGGGCGAGAGGGTGACC
ATGAACTGCAAGAGCAGCCAGAGCCTGCTGTACAGCACCAACCAGAAGAACTACCTGGCC
TGGTACCAGCAGAAGCCCGGCCAGAGCCCCAAGCTGCTGATCTACTGGGCCAGCACCAGG
GAGAGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACC
ATCAGCAGCGTGCAGGCCGAGGACGTGGCCGTGTACTACTGCCAGCAGTACTACAGCTAC
AGGACCTTCGGCGGCGGCACCAAGCTGGAGATCAAG
>P01274_F05 imgatuzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGGCATCAACAACTACCTGAACTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGAGGCTGATCTACAACACCAACAACCTGCAGACCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGAGTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCTGCAGCACAACAGCTTCCCCACCTTCGGCCAGGGC
ACCAAGCTGGAGATCAAG
>P01274_F06 infliximab
GACATCCTGCTGACCCAGAGCCCCGCCATCCTGAGCGTGAGCCCCGGCGAGAGGGTGAGC
TTCAGCTGCAGGGCCAGCCAGTTCGTGGGCAGCAGCATCCACTGGTACCAGCAGAGGACC
AACGGCAGCCCCAGGCTGCTGATCAAGTACGCCAGCGAGAGCATGAGCGGCATCCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAGCATCAACACCGTGGAGAGC
GAGGACATCGCCGACTACTACTGCCAGCAGAGCCACAGCTGGCCCTTCACCTTCGGCAGC
GGCACCAACCTGGAGGTGAAG
>P01274_F07 inotuzumab
GACGTGCAGGTGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGAGCAGCCAGAGCCTGGCCAACAGCTACGGCAACACCTTCCTGAGCTGG
TACCTGCACAAGCCCGGCAAGGCCCCCCAGCTGCTGATCTACGGCATCAGCAACAGGTTC
AGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATC
AGCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCTGCAGGGCACCCACCAGCCC
TACACCTTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P01274_F08 ipilimumab
GAGATCGTGCTGACCCAGAGCCCCGGCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGGGCAGCAGCTACCTGGCCTGGTACCAGCAGAAG
CCCGGCCAGGCCCCCAGGCTGCTGATCTACGGCGCCTTCAGCAGGGCCACCGGCATCCCC
GACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGGCTGGAG
CCCGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGGCAGCAGCCCCTGGACCTTCGGC
CAGGGCACCAAGGTGGAGATCAAG
>P01274_F09 ixekizumab
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACCCCCGGCCAGCCCGCCAGC
ATCAGCTGCAGGAGCAGCAGGAGCCTGGTGCACAGCAGGGGCAACACCTACCTGCACTGG
TACCTGCAGAAGCCCGGCCAGAGCCCCCAGCTGCTGATCTACAAGGTGAGCAACAGGTTC
ATCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAAGATC
AGCAGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCAGCCAGAGCACCCACCTGCCC
TTCACCTTCGGCCAGGGCACCAAGCTGGAGATCAAG
>P01274_F10 lampalizumab
GACATCCAGGTGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCATCACCAGCACCGACATCGACGACGACATGAACTGGTACCAGCAGAAGCCC
GGCAAGGTGCCCAAGCTGCTGATCAGCGGCGGCAACACCCTGAGGCCCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACGTGGCCACCTACTACTGCCTGCAGAGCGACAGCCTGCCCTACACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P01274_F11 lebrikizumab
GACATCGTGATGACCCAGAGCCCCGACAGCCTGAGCGTGAGCCTGGGCGAGAGGGCCACC
ATCAACTGCAGGGCCAGCAAGAGCGTGGACAGCTACGGCAACAGCTTCATGCACTGGTAC
CAGCAGAAGCCCGGCCAGCCCCCCAAGCTGCTGATCTACCTGGCCAGCAACCTGGAGAGC
GGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGC
AGCCTGCAGGCCGAGGACGTGGCCGTGTACTACTGCCAGCAGAACAACGAGGACCCCAGG
ACCTTCGGCGGCGGCACCAAGGTGGAGATCAAG
>P01274_F12 lenzilumab
GAGATCGTGCTGACCCAGAGCCCCGCCACCCTGAGCGTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGGGCACCAACGTGGCCTGGTACCAGCAGAAGCCC
GGCCAGGCCCCCAGGGTGCTGATCTACAGCACCAGCAGCAGGGCCACCGGCATCACCGAC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGGCTGGAGCCC
GAGGACTTCGCCGTGTACTACTGCCAGCAGTTCAACAAGAGCCCCCTGACCTTCGGCGGC
GGCACCAAGGTGGAGATCAAG
>P01274_G01 lintuzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCGAGAGCGTGGACAACTACGGCATCAGCTTCATGAACTGGTTC
CAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCCAGCAACCAGGGCAGC
GGCGTGCCCAGCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGC
AGCCTGCAGCCCGACGACTTCGCCACCTACTACTGCCAGCAGAGCAAGGAGGTGCCCTGG
ACCTTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P01274_G02 lirilumab
GAGATCGTGCTGACCCAGAGCCCCGTGACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCTACCTGGCCTGGTACCAGCAGAAGCCC
GGCCAGGCCCCCAGGCTGCTGATCTACGACGCCAGCAACAGGGCCACCGGCATCCCCGCC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGGAGCCC
GAGGACTTCGCCGTGTACTACTGCCAGCAGAGGAGCAACTGGATGTACACCTTCGGCCAG
GGCACCAAGCTGGAGATCAAG
>P01274_G03 lumiliximab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGACATCAGGTACTACCTGAACTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACGTGGCCAGCAGCCTGCAGAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGAGTTCACCCTGACCGTGAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCTGCAGGTGTACAGCACCCCCAGGACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P01274_G04 matuzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGCGCCAGCAGCAGCGTGACCTACATGTACTGGTACCAGCAGAAGCCCGGC
AAGGCCCCCAAGCTGCTGATCTACGACACCAGCAACCTGGCCAGCGGCGTGCCCAGCAGG
TTCAGCGGCAGCGGCAGCGGCACCGACTACACCTTCACCATCAGCAGCCTGCAGCCCGAG
GACATCGCCACCTACTACTGCCAGCAGTGGAGCAGCCACATCTTCACCTTCGGCCAGGGC
ACCAAGGTGGAGATCAAG
>P01274_G05 mavrilimumab
CAGAGCGTGCTGACCCAGCCCCCCAGCGTGAGCGGCGCCCCCGGCCAGAGGGTGACCATC
AGCTGCACCGGCAGCGGCAGCAACATCGGCGCCCCCTACGACGTGAGCTGGTACCAGCAG
CTGCCCGGCACCGCCCCCAAGCTGCTGATCTACCACAACAACAAGAGGCCCAGCGGCGTG
CCCGACAGGTTCAGCGGCAGCAAGAGCGGCACCAGCGCCAGCCTGGCCATCACCGGCCTG
CAGGCCGAGGACGAGGCCGACTACTACTGCGCCACCGTGGAGGCCGGCCTGAGCGGCAGC
GTGTTCGGCGGCGGCACCAAGCTGACCGTGCTG
>P01274_G06 mepolizumab
GACATCGTGATGACCCAGAGCCCCGACAGCCTGGCCGTGAGCCTGGGCGAGAGGGCCACC
ATCAACTGCAAGAGCAGCCAGAGCCTGCTGAACAGCGGCAACCAGAAGAACTACCTGGCC
TGGTACCAGCAGAAGCCCGGCCAGCCCCCCAAGCTGCTGATCTACGGCGCCAGCACCAGG
GAGAGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACC
ATCAGCAGCCTGCAGGCCGAGGACGTGGCCGTGTACTACTGCCAGAACGTGCACAGCTTC
CCCTTCACCTTCGGCGGCGGCACCAAGCTGGAGATCAAG
>P01274_G07 mogamulizumab
GACGTGCTGATGACCCAGAGCCCCCTGAGCCTGCCCGTGACCCCCGGCGAGCCCGCCAGC
ATCAGCTGCAGGAGCAGCAGGAACATCGTGCACATCAACGGCGACACCTACCTGGAGTGG
TACCTGCAGAAGCCCGGCCAGAGCCCCCAGCTGCTGATCTACAAGGTGAGCAACAGGTTC
AGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAAGATC
AGCAGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCTTCCAGGGCAGCCTGCTGCCC
TGGACCTTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P01274_G08 motavizumab
GACATCCAGATGACCCAGAGCCCCAGCACCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGCGCCAGCAGCAGGGTGGGCTACATGCACTGGTACCAGCAGAAGCCCGGC
AAGGCCCCCAAGCTGCTGATCTACGACACCAGCAAGCTGGCCAGCGGCGTGCCCAGCAGG
TTCAGCGGCAGCGGCAGCGGCACCGAGTTCACCCTGACCATCAGCAGCCTGCAGCCCGAC
GACTTCGCCACCTACTACTGCTTCCAGGGCAGCGGCTACCCCTTCACCTTCGGCGGCGGC
ACCAAGGTGGAGATCAAG
>P01274_G09 muromonab
CAGATCGTGCTGACCCAGAGCCCCGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACC
ATGACCTGCAGCGCCAGCAGCAGCGTGAGCTACATGAACTGGTACCAGCAGAAGAGCGGC
ACCAGCCCCAAGAGGTGGATCTACGACACCAGCAAGCTGGCCAGCGGCGTGCCCGCCCAC
TTCAGGGGCAGCGGCAGCGGCACCAGCTACAGCCTGACCATCAGCGGCATGGAGGCCGAG
GACGCCGCCACCTACTACTGCCAGCAGTGGAGCAGCAACCCCTTCACCTTCGGCAGCGGC
ACCAAGCTGGAGATCAAG
>P01274_G10 natalizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAAGACCAGCCAGGACATCAACAAGTACATGGCCTGGTACCAGCAGACCCCC
GGCAAGGCCCCCAGGCTGCTGATCCACTACACCAGCGCCCTGCAGCCCGGCATCCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCAGGGACTACACCTTCACCATCAGCAGCCTGCAGCCC
GAGGACATCGCCACCTACTACTGCCTGCAGTACGACAACCTGTGGACCTTCGGCCAGGGC
ACCAAGGTGGAGATCAAG
>P01274_G11 necitumumab
GAGATCGTGATGACCCAGAGCCCCGCCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCTACCTGGCCTGGTACCAGCAGAAGCCC
GGCCAGGCCCCCAGGCTGCTGATCTACGACGCCAGCAACAGGGCCACCGGCATCCCCGCC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGGAGCCC
GAGGACTTCGCCGTGTACTACTGCCACCAGTACGGCAGCACCCCCCTGACCTTCGGCGGC
GGCACCAAGGCCGAGATCAAG
>P01274_G12 nimotuzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGAGCAGCCAGAACATCGTGCACAGCAACGGCAACACCTACCTGGACTGG
TACCAGCAGACCCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGTGAGCAACAGGTTC
AGCGGCGTGCCCAGCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCTTCACCATC
AGCAGCCTGCAGCCCGAGGACATCGCCACCTACTACTGCTTCCAGTACAGCCACGTGCCC
TGGACCTTCGGCCAGGGCACCAAGCTGCAGATCACC
>P01274_H01 nivolumab
GAGATCGTGCTGACCCAGAGCCCCGCCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCTACCTGGCCTGGTACCAGCAGAAGCCC
GGCCAGGCCCCCAGGCTGCTGATCTACGACGCCAGCAACAGGGCCACCGGCATCCCCGCC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGGAGCCC
GAGGACTTCGCCGTGTACTACTGCCAGCAGAGCAGCAACTGGCCCAGGACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P01274_H02 obinutuzumab
GACATCGTGATGACCCAGACCCCCCTGAGCCTGCCCGTGACCCCCGGCGAGCCCGCCAGC
ATCAGCTGCAGGAGCAGCAAGAGCCTGCTGCACAGCAACGGCATCACCTACCTGTACTGG
TACCTGCAGAAGCCCGGCCAGAGCCCCCAGCTGCTGATCTACCAGATGAGCAACCTGGTG
AGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAAGATC
AGCAGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCGCCCAGAACCTGGAGCTGCCC
TACACCTTCGGCGGCGGCACCAAGGTGGAGATCAAG
>P01274_H03 ocrelizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCAGCAGCGTGAGCTACATGCACTGGTACCAGCAGAAGCCCGGC
AAGGCCCCCAAGCCCCTGATCTACGCCCCCAGCAACCTGGCCAGCGGCGTGCCCAGCAGG
TTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGAG
GACTTCGCCACCTACTACTGCCAGCAGTGGAGCTTCAACCCCCCCACCTTCGGCCAGGGC
ACCAAGGTGGAGATCAAG
>P01274_H04 ofatumumab
GAGATCGTGCTGACCCAGAGCCCCGCCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCTACCTGGCCTGGTACCAGCAGAAGCCC
GGCCAGGCCCCCAGGCTGCTGATCTACGACGCCAGCAACAGGGCCACCGGCATCCCCGCC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGGAGCCC
GAGGACTTCGCCGTGTACTACTGCCAGCAGAGGAGCAACTGGCCCATCACCTTCGGCCAG
GGCACCAGGCTGGAGATCAAG
>P01274_H05 olaratumab
GAGATCGTGCTGACCCAGAGCCCCGCCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCTACCTGGCCTGGTACCAGCAGAAGCCC
GGCCAGGCCCCCAGGCTGCTGATCTACGACGCCAGCAACAGGGCCACCGGCATCCCCGCC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGGAGCCC
GAGGACTTCGCCGTGTACTACTGCCAGCAGAGGAGCAACTGGCCCCCCGCCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P01274_H06 olokizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCCAGGCCAGCCAGGACATCGGCATCAGCCTGAGCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACAACGCCAACAACCTGGCCGACGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCTGCAGCACAACAGCGCCCCCTACACCTTCGGCCAG
GGCACCAAGCTGGAGATCAAG
>P01274_H07 omalizumab
GACATCCAGCTGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGAGCGTGGACTACGACGGCGACAGCTACATGAACTGGTAC
CAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCCAGCTACCTGGAGAGC
GGCGTGCCCAGCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGC
AGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGAGCCACGAGGACCCCTAC
ACCTTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P01274_H08 onartuzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAAGAGCAGCCAGAGCCTGCTGTACACCAGCAGCCAGAAGAACTACCTGGCC
TGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACTGGGCCAGCACCAGG
GAGAGCGGCGTGCCCAGCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACC
ATCAGCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGTACTACGCCTAC
CCCTGGACCTTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P01274_H09 otelixizumab
GACATCCAGCTGACCCAGCCCAACAGCGTGAGCACCAGCCTGGGCAGCACCGTGAAGCTG
AGCTGCACCCTGAGCAGCGGCAACATCGAGAACAACTACGTGCACTGGTACCAGCTGTAC
GAGGGCAGGAGCCCCACCACCATGATCTACGACGACGACAAGAGGCCCGACGGCGTGCCC
GACAGGTTCAGCGGCAGCATCGACAGGAGCAGCAACAGCGCCTTCCTGACCATCCACAAC
GTGGCCATCGAGGACGAGGCCATCTACTTCTGCCACAGCTACGTGAGCAGCTTCAACGTG
TTCGGCGGCGGCACCAAGCTGACCGTGCTG
>P01274_H10 otlertuzumab
GAGATCGTGCTGACCCAGAGCCCCGCCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCGAGAACGTGTACAGCTACCTGGCCTGGTACCAGCAGAAGCCC
GGCCAGGCCCCCAGGCTGCTGATCTACTTCGCCAAGACCCTGGCCGAGGGCATCCCCGCC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGGAGCCC
GAGGACTTCGCCGTGTACTACTGCCAGCACCACAGCGACAACCCCTGGACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P01274_H11 ozanezumab
GACATCGTGATGACCCAGAGCCCCCTGAGCAACCCCGTGACCCTGGGCCAGCCCGTGAGC
ATCAGCTGCAGGAGCAGCAAGAGCCTGCTGTACAAGGACGGCAAGACCTACCTGAACTGG
TTCCTGCAGAGGCCCGGCCAGAGCCCCCAGCTGCTGATCTACCTGATGAGCACCAGGGCC
AGCGGCGTGCCCGACAGGTTCAGCGGCGGCGGCAGCGGCACCGACTTCACCCTGAAGATC
AGCAGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCCAGCAGCTGGTGGAGTACCCC
CTGACCTTCGGCCAGGGCACCAAGCTGGAGATCAAG
>P01274_H12 palivizumab
GACATCCAGATGACCCAGAGCCCCAGCACCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAAGTGCCAGCTGAGCGTGGGCTACATGCACTGGTACCAGCAGAAGCCCGGC
AAGGCCCCCAAGCTGCTGATCTACGACACCAGCAAGCTGGCCAGCGGCGTGCCCAGCAGG
TTCAGCGGCAGCGGCAGCGGCACCGAGTTCACCCTGACCATCAGCAGCCTGCAGCCCGAC
GACTTCGCCACCTACTACTGCTTCCAGGGCAGCGGCTACCCCTTCACCTTCGGCGGCGGC
ACCAAGCTGGAGATCAAG
>P00483_A01 panitumumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCCAGGCCAGCCAGGACATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACGACGCCAGCAACCTGGAGACCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCTTCACCATCAGCAGCCTGCAGCCC
GAGGACATCGCCACCTACTTCTGCCAGCACTTCGACCACCTGCCCCTGGCCTTCGGCGGC
GGCACCAAGGTGGAGATCAAG
>P00483_A02 panobacumab
GACGTGGTGATGACCCAGAGCCCCCTGAGCCTGCCCGTGACCCTGGGCCAGCCCGCCAGC
ATCAGCTGCAGGAGCAGCCAGAGCCTGGTGTACAGCGACGGCAACACCTACCTGAACTGG
TTCCAGCAGAGGCCCGGCCAGAGCCCCAGGAGGCTGATCTACAAGGTGAGCAACAGGGAC
AGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAAGATC
AGCAGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCATGCAGGGCACCCACTGGCCC
CTGACCTTCGGCGGCGGCACCAAGGTGGAGATCAAG
>P00483_A03 parsatuzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGACCAGCCAGAGCCTGGTGCACATCAACGCCATCACCTACCTGCACTGG
TACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAGGGTGAGCAACAGGTTC
AGCGGCGTGCCCAGCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATC
AGCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCGGCCAGAGCACCCACGTGCCC
CTGACCTTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P00483_A04 patritumab
GACATCGAGATGACCCAGAGCCCCGACAGCCTGGCCGTGAGCCTGGGCGAGAGGGCCACC
ATCAACTGCAGGAGCAGCCAGAGCGTGCTGTACAGCAGCAGCAACAGGAACTACCTGGCC
TGGTACCAGCAGAACCCCGGCCAGCCCCCCAAGCTGCTGATCTACTGGGCCAGCACCAGG
GAGAGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACC
ATCAGCAGCCTGCAGGCCGAGGACGTGGCCGTGTACTACTGCCAGCAGTACTACAGCACC
CCCAGGACCTTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P00483_A05 pembrolizumab
GAGATCGTGCTGACCCAGAGCCCCGCCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCAAGGGCGTGAGCACCAGCGGCTACAGCTACCTGCACTGGTAC
CAGCAGAAGCCCGGCCAGGCCCCCAGGCTGCTGATCTACCTGGCCAGCTACCTGGAGAGC
GGCGTGCCCGCCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGC
AGCCTGGAGCCCGAGGACTTCGCCGTGTACTACTGCCAGCACAGCAGGGACCTGCCCCTG
ACCTTCGGCGGCGGCACCAAGGTGGAGATCAAG
>P00483_A06 pertuzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAAGGCCAGCCAGGACGTGAGCATCGGCGTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACAGCGCCAGCTACAGGTACACCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGTACTACATCTACCCCTACACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00483_A07 pinatuzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGAGCAGCCAGAGCATCGTGCACAGCGTGGGCAACACCTTCCTGGAGTGG
TACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGTGAGCAACAGGTTC
AGCGGCGTGCCCAGCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATC
AGCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCTTCCAGGGCAGCCAGTTCCCC
TACACCTTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P00483_A08 polatuzumab
GACATCCAGCTGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAAGGCCAGCCAGAGCGTGGACTACGAGGGCGACAGCTTCCTGAACTGGTAC
CAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGCCGCCAGCAACCTGGAGAGC
GGCGTGCCCAGCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGC
AGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGAGCAACGAGGACCCCCTG
ACCTTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P00483_A09 ponezumab
GACGTGGTGATGACCCAGAGCCCCCTGAGCCTGCCCGTGACCCTGGGCCAGCCCGCCAGC
ATCAGCTGCAAGAGCAGCCAGAGCCTGCTGTACAGCGACGCCAAGACCTACCTGAACTGG
TTCCAGCAGAGGCCCGGCCAGAGCCCCAGGAGGCTGATCTACCAGATCAGCAGGCTGGAC
CCCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAAGATC
AGCAGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCCTGCAGGGCACCCACTACCCC
GTGCTGTTCGGCCAGGGCACCAGGCTGGAGATCAAG
>P00483_A10 radretumab
GAGATCGTGCTGACCCAGAGCCCCGGCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCAGCTTCCTGGCCTGGTACCAGCAGAAG
CCCGGCCAGGCCCCCAGGCTGCTGATCTACTACGCCAGCAGCAGGGCCACCGGCATCCCC
GACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGGCTGGAG
CCCGAGGACTTCGCCGTGTACTACTGCCAGCAGACCGGCAGGATCCCCCCCACCTTCGGC
CAGGGCACCAAGGTGGAGATCAAG
>P00483_A11 ramucirumab
GACATCCAGATGACCCAGAGCCCCAGCAGCGTGAGCGCCAGCATCGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGGCATCGACAACTGGCTGGGCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACGACGCCAGCAACCTGGACACCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCTACTTCACCCTGACCATCAGCAGCCTGCAGGCC
GAGGACTTCGCCGTGTACTTCTGCCAGCAGGCCAAGGCCTTCCCCCCCACCTTCGGCGGC
GGCACCAAGGTGGACATCAAG
>P00483_A12 ranibizumab
GACATCCAGCTGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGCGCCAGCCAGGACATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGGTGCTGATCTACTTCACCAGCAGCCTGCACAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGTACAGCACCGTGCCCTGGACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00483_B01 reslizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCCTGGCCAGCGAGGGCATCAGCAGCTACCTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACGGCGCCAACAGCCTGCAGACCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGCCACCGACTACACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGAGCTACAAGTTCCCCAACACCTTCGGCCAG
GGCACCAAGGTGGAGGTGAAG
>P00483_B02 rilotumumab
GAGATCGTGATGACCCAGAGCCCCGCCACCCTGAGCGTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGGACAGCAACCTGGCCTGGTACAGGCAGAAGCCC
GGCCAGGCCCCCAGGCTGCTGATCTACGGCGCCAGCACCAGGGCCACCGGCATCCCCGCC
AGGTTCAGCGGCAGCGGCAGCGGCACCGAGTTCACCCTGACCATCAGCAGCCTGCAGAGC
GAGGACTTCGCCGTGTACTACTGCCAGCAGTACATCAACTGGCCCCCCATCACCTTCGGC
CAGGGCACCAGGCTGGAGATCAAG
>P00483_B03 rituximab
CAGATCGTGCTGAGCCAGAGCCCCGCCATCCTGAGCGCCAGCCCCGGCGAGAAGGTGACC
ATGACCTGCAGGGCCAGCAGCAGCGTGAGCTACATCCACTGGTTCCAGCAGAAGCCCGGC
AGCAGCCCCAAGCCCTGGATCTACGCCACCAGCAACCTGGCCAGCGGCGTGCCCGTGAGG
TTCAGCGGCAGCGGCAGCGGCACCAGCTACAGCCTGACCATCAGCAGGGTGGAGGCCGAG
GACGCCGCCACCTACTACTGCCAGCAGTGGACCAGCAACCCCCCCACCTTCGGCGGCGGC
ACCAAGCTGGAGATCAAG
>P00483_B04 robatumumab
GAGATCGTGCTGACCCAGAGCCCCGGCACCCTGAGCGTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCATCGGCAGCAGCCTGCACTGGTACCAGCAGAAGCCC
GGCCAGGCCCCCAGGCTGCTGATCAAGTACGCCAGCCAGAGCCTGAGCGGCATCCCCGAC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGGCTGGAGCCC
GAGGACTTCGCCGTGTACTACTGCCACCAGAGCAGCAGGCTGCCCCACACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00483_B05 romosozumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGACATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACTACACCAGCAGGCTGCTGAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGGGCGACACCCTGCCCTACACCTTCGGCGGC
GGCACCAAGGTGGAGATCAAG
>P00483_B06 sarilumab
GACATCCAGATGACCCAGAGCCCCAGCAGCGTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGGCATCAGCAGCTGGCTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACGGCGCCAGCAGCCTGGAGAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCAGCTACTACTGCCAGCAGGCCAACAGCTTCCCCTACACCTTCGGCCAG
GGCACCAAGCTGGAGATCAAG
>P00483_B07 secukinumab
GAGATCGTGCTGACCCAGAGCCCCGGCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCAGCTACCTGGCCTGGTACCAGCAGAAG
CCCGGCCAGGCCCCCAGGCTGCTGATCTACGGCGCCAGCAGCAGGGCCACCGGCATCCCC
GACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGGCTGGAG
CCCGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGGCAGCAGCCCCTGCACCTTCGGC
CAGGGCACCAGGCTGGAGATCAAG
>P00483_B08 seribantumab
CAGAGCGCCCTGACCCAGCCCGCCAGCGTGAGCGGCAGCCCCGGCCAGAGCATCACCATC
AGCTGCACCGGCACCAGCAGCGACGTGGGCAGCTACAACGTGGTGAGCTGGTACCAGCAG
CACCCCGGCAAGGCCCCCAAGCTGATCATCTACGAGGTGAGCCAGAGGCCCAGCGGCGTG
AGCAACAGGTTCAGCGGCAGCAAGAGCGGCAACACCGCCAGCCTGACCATCAGCGGCCTG
CAGACCGAGGACGAGGCCGACTACTACTGCTGCAGCTACGCCGGCAGCAGCATCTTCGTG
ATCTTCGGCGGCGGCACCAAGGTGACCGTGCTG
>P00483_B09 sifalimumab
GAGATCGTGCTGACCCAGAGCCCCGGCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCACCTACCTGGCCTGGTACCAGCAGAAG
CCCGGCCAGGCCCCCAGGCTGCTGATCTACGGCGCCAGCAGCAGGGCCACCGGCATCCCC
GACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGGCTGGAG
CCCGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGGCAGCAGCCCCAGGACCTTCGGC
CAGGGCACCAAGGTGGAGATCAAG
>P00483_B10 siltuximab
CAGATCGTGCTGATCCAGAGCCCCGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACC
ATGACCTGCAGCGCCAGCAGCAGCGTGAGCTACATGTACTGGTACCAGCAGAAGCCCGGC
AGCAGCCCCAGGCTGCTGATCTACGACACCAGCAACCTGGCCAGCGGCGTGCCCGTGAGG
TTCAGCGGCAGCGGCAGCGGCACCAGCTACAGCCTGACCATCAGCAGGATGGAGGCCGAG
GACGCCGCCACCTACTACTGCCAGCAGTGGAGCGGCTACCCCTACACCTTCGGCGGCGGC
ACCAAGCTGGAGATCAAG
>P00483_B11 simtuzumab
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACCCCCGGCCAGCCCGCCAGC
ATCAGCTGCAGGAGCAGCAAGAGCCTGCTGCACAGCAACGGCAACACCTACCTGTACTGG
TTCCTGCAGAAGCCCGGCCAGAGCCCCCAGTTCCTGATCTACAGGATGAGCAACCTGGCC
AGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAAGATC
AGCAGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCATGCAGCACCTGGAGTACCCC
TACACCTTCGGCGGCGGCACCAAGGTGGAGATCAAG
>P00483_B12 sirukumab
GAGATCGTGCTGACCCAGAGCCCCGCCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGCGCCAGCATCAGCGTGAGCTACATGTACTGGTACCAGCAGAAGCCCGGC
CAGGCCCCCAGGCTGCTGATCTACGACATGAGCAACCTGGCCAGCGGCATCCCCGCCAGG
TTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGGAGCCCGAG
GACTTCGCCGTGTACTACTGCATGCAGTGGAGCGGCTACCCCTACACCTTCGGCGGCGGC
ACCAAGGTGGAGATCAAG
>P00483_C01 tabalumab
GAGATCGTGCTGACCCAGAGCCCCGCCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGGTACCTGGCCTGGTACCAGCAGAAGCCC
GGCCAGGCCCCCAGGCTGCTGATCTACGACGCCAGCAACAGGGCCACCGGCATCCCCGCC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACAGCACCCTGACCATCAGCAGCCTGGAGCCC
GAGGACTTCGCCGTGTACTACTGCCAGCAGAGGAGCAACTGGCCCAGGACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00483_C02 tanezumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGAGCATCAGCAACAACCTGAACTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACTACACCAGCAGGTTCCACAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCTTCACCATCAGCAGCCTGCAGCCC
GAGGACATCGCCACCTACTACTGCCAGCAGGAGCACACCCTGCCCTACACCTTCGGCCAG
GGCACCAAGCTGGAGATCAAG
>P00483_C03 teplizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGCGCCAGCAGCAGCGTGAGCTACATGAACTGGTACCAGCAGACCCCCGGC
AAGGCCCCCAAGAGGTGGATCTACGACACCAGCAAGCTGGCCAGCGGCGTGCCCAGCAGG
TTCAGCGGCAGCGGCAGCGGCACCGACTACACCTTCACCATCAGCAGCCTGCAGCCCGAG
GACATCGCCACCTACTACTGCCAGCAGTGGAGCAGCAACCCCTTCACCTTCGGCCAGGGC
ACCAAGCTGCAGATCACC
>P00483_C04 tigatuzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAAGGCCAGCCAGGACGTGGGCACCGCCGTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACTGGGCCAGCACCAGGCACACCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGTACAGCAGCTACAGGACCTTCGGCCAGGGC
ACCAAGGTGGAGATCAAG
>P00483_C05 tildrakizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGACCAGCGAGAACATCTACAGCTACCTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACAACGCCAAGACCCTGGCCGAGGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCACCACTACGGCATCCCCTTCACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00483_C06 tocilizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGACATCAGCAGCTACCTGAACTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACTACACCAGCAGGCTGCACAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCTTCACCATCAGCAGCCTGCAGCCC
GAGGACATCGCCACCTACTACTGCCAGCAGGGCAACACCCTGCCCTACACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00483_C07 tovetumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGAGC
ATCACCTGCAGGCCCAGCCAGAGCTTCAGCAGGTACATCAACTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCCACGCCGCCAGCAGCCTGGTGGGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGACCTACAGCAACCCCCCCATCACCTTCGGC
CAGGGCACCAGGCTGGAGATGAAG
>P00483_C08 tralokinumab
AGCTACGTGCTGACCCAGCCCCCCAGCGTGAGCGTGGCCCCCGGCAAGACCGCCAGGATC
ACCTGCGGCGGCAACATCATCGGCAGCAAGCTGGTGCACTGGTACCAGCAGAAGCCCGGC
CAGGCCCCCGTGCTGGTGATCTACGACGACGGCGACAGGCCCAGCGGCATCCCCGAGAGG
TTCAGCGGCAGCAACAGCGGCAACACCGCCACCCTGACCATCAGCAGGGTGGAGGCCGGC
GACGAGGCCGACTACTACTGCCAGGTGTGGGACACCGGCAGCGACCCCGTGGTGTTCGGC
GGCGGCACCAAGCTGACCGTGCTG
>P00483_C09 trastuzumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGACGTGAACACCGCCGTGGCCTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACAGCGCCAGCTTCCTGTACAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCAGGAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGCACTACACCACCCCCCCCACCTTCGGCCAG
GGCACCAAGGTGGAGATCAAG
>P00483_C10 tremelimumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGAGCATCAACAGCTACCTGGACTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACGCCGCCAGCAGCCTGCAGAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGTACTACAGCACCCCCTTCACCTTCGGCCCC
GGCACCAAGGTGGAGATCAAG
>P00483_C11 urelumab
GAGATCGTGCTGACCCAGAGCCCCGCCACCCTGAGCCTGAGCCCCGGCGAGAGGGCCACC
CTGAGCTGCAGGGCCAGCCAGAGCGTGAGCAGCTACCTGGCCTGGTACCAGCAGAAGCCC
GGCCAGGCCCCCAGGCTGCTGATCTACGACGCCAGCAACAGGGCCACCGGCATCCCCGCC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGGAGCCC
GAGGACTTCGCCGTGTACTACTGCCAGCAGAGGAGCAACTGGCCCCCCGCCCTGACCTTC
GGCGGCGGCACCAAGGTGGAGATCAAG
>P00483_C12 ustekinumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGGCATCAGCAGCTGGCTGGCCTGGTACCAGCAGAAGCCC
GAGAAGGCCCCCAAGAGCCTGATCTACGCCGCCAGCAGCCTGCAGAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGTACAACATCTACCCCTACACCTTCGGCCAG
GGCACCAAGCTGGAGATCAAG
>P00483_D01 vedolizumab
GACGTGGTGATGACCCAGAGCCCCCTGAGCCTGCCCGTGACCCCCGGCGAGCCCGCCAGC
ATCAGCTGCAGGAGCAGCCAGAGCCTGGCCAAGAGCTACGGCAACACCTACCTGAGCTGG
TACCTGCAGAAGCCCGGCCAGAGCCCCCAGCTGCTGATCTACGGCATCAGCAACAGGTTC
AGCGGCGTGCCCGACAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAAGATC
AGCAGGGTGGAGGCCGAGGACGTGGGCGTGTACTACTGCCTGCAGGGCACCCACCAGCCC
TACACCTTCGGCCAGGGCACCAAGGTGGAGATCAAG
>P00483_D02 veltuzumab
GACATCCAGCTGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATGACCTGCAGGGCCAGCAGCAGCGTGAGCTACATCCACTGGTTCCAGCAGAAGCCCGGC
AAGGCCCCCAAGCCCTGGATCTACGCCACCAGCAACCTGGCCAGCGGCGTGCCCGTGAGG
TTCAGCGGCAGCGGCAGCGGCACCGACTACACCTTCACCATCAGCAGCCTGCAGCCCGAG
GACATCGCCACCTACTACTGCCAGCAGTGGACCAGCAACCCCCCCACCTTCGGCGGCGGC
ACCAAGCTGGAGATCAAG
>P00483_D03 visilizumab
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGCGCCAGCAGCAGCGTGAGCTACATGAACTGGTACCAGCAGAAGCCCGGC
AAGGCCCCCAAGAGGCTGATCTACGACACCAGCAAGCTGGCCAGCGGCGTGCCCAGCAGG
TTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGAG
GACTTCGCCACCTACTACTGCCAGCAGTGGAGCAGCAACCCCCCCACCTTCGGCGGCGGC
ACCAAGGTGGAGATCAAG
>P00483_D04 zalutumumab
GCCATCCAGCTGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGACATCAGCAGCGCCCTGGTGTGGTACCAGCAGAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACGACGCCAGCAGCCTGGAGAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGAGAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGTTCAACAGCTACCCCCTGACCTTCGGCGGC
GGCACCAAGGTGGAGATCAAG
>P00483_D05 zanolimumab
GACATCCAGATGACCCAGAGCCCCAGCAGCGTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATCACCTGCAGGGCCAGCCAGGACATCAGCAGCTGGCTGGCCTGGTACCAGCACAAGCCC
GGCAAGGCCCCCAAGCTGCTGATCTACGCCGCCAGCAGCCTGCAGAGCGGCGTGCCCAGC
AGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCC
GAGGACTTCGCCACCTACTACTGCCAGCAGGCCAACAGCTTCCCCTACACCTTCGGCCAG
GGCACCAAGCTGGAGATCAAG
